Homology Medicines Regains Global Rights To Novartis Ophthalmology Program

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing technology platform for an ophthalmic target.

  • Novartis had concluded the collaboration and licensing agreement with Homology announced in 2017 to pursue other opportunities in their pipeline.
  • The company has generated in vivo data in two different eye targets.
  • "AAVHSC vectors can edit the back of the eye, and we plan to share additional data from the ophthalmology program at a scientific meeting in May," said Arthur Tzianabos, President and CEO of Homology Medicines.
  • Price Action: FIXX shares were trading 3.54% higher at $11.12, and NVS shares were up 0.8% at $86.61 in market trading hours on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralophthalmology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!